About Cutaneous Lymphoma

Press Releases

07/28/2011 : Yaupon Therapeutics, Inc. Submits New Drug Application For Proprietaty Gel Formulation Of Mechlorethamine Hydrochloride
Requesting U.S. marketing approval for the topical treatment of early stage (stages I-IIA) mycosis fungoides, a common type of Cutaneous T-Cell Lymphoma
06/16/2011 : FDA Grants Accelerated Approval of Istodax®
FDA Grants Accelerated Approval of Istodax® As Treatment For Patients With Peripheral T-Cell Lymphoma Who Have Received At Least One Prior Therapy
06/01/2011 : Cutaneous Lymphoma Foundation CEO, Jennifer Viano, Talks with OncUView.tv at the American Society of Clinical Oncology's Annual Meeting
Cutaneous Lymphoma Foundation CEO, Jennifer Viano, Talks with OncUView.tv at the American Society of Clinical Oncology’s Annual Meeting
03/11/2011 : Cutaneous Lymphoma Foundation Featured in USA Today
Judy Jones, President Emeritus of the Cutaneous Lymphoma Foundation and President of the Coalition of Skin Diseases, writes about the burden of skin disease in USA Today
12/05/2010 : Updated Results from FOLOTYN® Phase 1 Dose Finding Study Demonstrates Activity in Relapsed or Refractory Cutaneous T-Cell Lymphoma
Allos Therapeutics, Inc. (NASDAQ: ALTH) today reported updated results from the Company’s Phase 1 dose-finding study of FOLOTYN® (pralatrexate injection) which supports the selection of 15 mg/m2 weekly for three weeks out of a four-week cycle as the optimal starting dose and schedule for further evaluation in patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL). Data were presented at the 52nd American Society of Hematology (ASH) Annual Meeting in Orlando, Florida.
12/04/2010 : Allos Therapeutics Reports New Analyses of FOLOTYN® Data from PROPEL trial in Relapsed or Refractory Peripheral T-Cell Lymphoma
Allos Therapeutics, Inc. (NASDAQ: ALTH) today reported new analyses of data from the Company's pivotal PROPEL trial of FOLOTYN® (pralatrexate injection) in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) at the 52nd American Society of Hematology (ASH) Annual Meeting held in Orlando, Florida.
Syndicate content